tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Koch K et al. CP-123,369: a potent, orally active immunosuppressive agent. 1995 Inflamm. Res. pmid:8548388
Lionetti P et al. Mucosal adaptation and destruction in response to lamina propria T cell activation in explants of human fetal intestine. 1995 Adv. Exp. Med. Biol. pmid:8525974
Ku YM et al. Compatibility of tacrolimus injection with cimetidine hydrochloride injection in 0.9% sodium chloride injection. 1995 Am J Health Syst Pharm pmid:8528874
Arreaza G et al. Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506. 1995 J. Clin. Endocrinol. Metab. pmid:8530625
Braun W et al. Three-dimensional structure and actions of immunosuppressants and their immunophilins. 1995 FASEB J. pmid:7529736
Zarnt T et al. Time-dependent inhibition of peptidylprolyl cis-trans-isomerases by FK506 is probably due to cis-trans isomerization of the inhibitor's imide bond. 1995 Biochem. J. pmid:7529995
Wang CR et al. T cell receptor-mediated signaling events in CD4+CD8+ thymocytes undergoing thymic selection: requirement of calcineurin activation for thymic positive selection but not negative selection. 1995 J. Exp. Med. pmid:7532685
Wera S et al. Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. 1995 FEBS Lett. pmid:7530217
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Van Thiel DH et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7532912
Ning YM and Sanchez ER Stabilization in vitro of the untransformed glucocorticoid receptor complex of S49 lymphocytes by the immunophilin ligand FK506. 1995 J. Steroid Biochem. Mol. Biol. pmid:7532989
Teraoka S et al. Effect of rescue therapy using FK 506 on relapsing rejection after combined pancreas and kidney transplantation. 1995 Transplant. Proc. pmid:7533381
Fay JW et al. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. 1995 Transplant. Proc. pmid:7533383
Murase N et al. Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. 1995 Transplant. Proc. pmid:7533386
Zeevi A et al. Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. 1995 Transplant. Proc. pmid:7533388
Watanabe K et al. Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. 1995 Transplant. Proc. pmid:7533389
Wennberg L et al. Efficacy of various immunosuppressive drugs in preventing pig-to-rat islet xenograft rejection. 1995 Transplant. Proc. pmid:7533391
Scantlebury VP et al. Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. 1995 Transplant. Proc. pmid:7533436
Hanafusa T et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. 1995 Transplant. Proc. pmid:7533440
Bundick RV et al. The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity. 1995 Clin. Exp. Immunol. pmid:7533681
Hirakata Y et al. Influence of various immunosuppressive agents on the occurrence of endogenous bacteraemia in mice. 1995 J. Med. Microbiol. pmid:7533840
Gregory CR et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 1995 Transplantation pmid:7533955
Tumlin JA et al. Expression of calcineurin activity and alpha-subunit isoforms in specific segments of the rat nephron. 1995 Am. J. Physiol. pmid:7485542
Furukawa F et al. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. 1995 Arch. Dermatol. Res. pmid:7487142
Lapa e Silva JR et al. Modulation of the bronchial inflammation in sensitized guinea-pigs by FK506, nedocromil sodium and dexamethasone. 1995 Eur. Respir. J. pmid:7489798
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Min Z and Jones NF Limb transplantation in rats: immunosuppression with FK-506. 1995 J Hand Surg Am pmid:7536766
Petrides AS [Do immunosuppressive agents really impair glucose tolerance in liver transplant patients?]. 1995 Z Gastroenterol pmid:7571761
Lyons WE et al. Neuronal regeneration enhances the expression of the immunophilin FKBP-12. 1995 J. Neurosci. pmid:7536825
Thomson AW and Bonham CA Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. 1995 Adv. Exp. Med. Biol. pmid:7572394
Wortis HH et al. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7536930
Bang H et al. Activation of Ca2+ signaling in neutrophils by the mast cell-released immunophilin FKBP12. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7536932
Masaki Y et al. Cellular basis of acquired immunologic tolerance following total bowel transplantation in rats. I. Relation between donor lymphocyte chimerism and host-cell-mediated immunity. 1995 Transplant. Proc. pmid:7536971
Garrett-Engele P et al. Calcineurin, the Ca2+/calmodulin-dependent protein phosphatase, is essential in yeast mutants with cell integrity defects and in mutants that lack a functional vacuolar H(+)-ATPase. 1995 Mol. Cell. Biol. pmid:7542741
Baughman G et al. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. 1995 Mol. Cell. Biol. pmid:7542743
Warty V et al. Tacrolimus analysis: a comparison of different methods and matrices. 1995 Ther Drug Monit pmid:7542809
Freeman DJ et al. Stability of FK 506 in whole blood samples. 1995 Ther Drug Monit pmid:7542810
Strumph P et al. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. 1995 Transplantation pmid:7542815
Dumont FJ et al. Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. 1995 Cell. Immunol. pmid:7538911
Theopold U et al. FKBP39, a Drosophila member of a family of proteins that bind the immunosuppressive drug FK506. 1995 Gene pmid:7538962
Zhao Y et al. Calcineurin activation protects T cells from glucocorticoid-induced apoptosis. 1995 J. Immunol. pmid:7539018
Bronsther O et al. Liver transplantation for HBV-related disease under immunosuppression with tacrolimus: an experience with 78 consecutive cases. 1995 J Okla State Med Assoc pmid:7539077
Hoshino H et al. Effects of FK506 on an experimental model of colitis in rats. 1995 Aliment. Pharmacol. Ther. pmid:7544633
Firdaous I et al. HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients. 1995 Clin. Chem. pmid:7544705
Ingels SC et al. Stability of FK506 (tacrolimus) in whole-blood specimens. 1995 Clin. Chem. pmid:7544707
Hikita N et al. Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. 1995 Curr. Eye Res. pmid:7540967
Takizawa H et al. Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506. 1995 Digestion pmid:7544748
Cardenas ME et al. Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. 1995 EMBO J. pmid:7540976
Sher LS and Makowka L Immunosuppression: now we have choices. 1995 Hepatology pmid:7544759
Madsen KL et al. FK506 increases permeability in rat intestine by inhibiting mitochondrial function. 1995 Gastroenterology pmid:7540994
Yang WM et al. Cyclophilin A and FKBP12 interact with YY1 and alter its transcriptional activity. 1995 J. Biol. Chem. pmid:7541038
Kawamura A and Su MS Interaction of FKBP12-FK506 with calcineurin A at the B subunit-binding domain. 1995 J. Biol. Chem. pmid:7541044
Rao PN et al. Reduction of FK-506 requirements by combination with polyethylene glycol superoxide dismutase in orthotopic rat liver transplantation. 1995 J. Allergy Clin. Immunol. pmid:7541060
Lauerma AI Immunomodulation of contact dermatitis. 1995 Curr. Probl. Dermatol. pmid:7587333
Wera S et al. Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. 1995 Endocr. Res. pmid:7588431
Cameron AM et al. Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. 1995 Cell pmid:8521476
Stoller G et al. A ribosome-associated peptidyl-prolyl cis/trans isomerase identified as the trigger factor. 1995 EMBO J. pmid:7588623
Tamura K FK506: mechanism of immunosuppression and adverse-effects. 1995 J Toxicol Sci pmid:8531246
Farcasanu IC et al. Protein phosphatase 2B of Saccharomyces cerevisiae is required for tolerance to manganese, in blocking the entry of ions into the cells. 1995 Eur. J. Biochem. pmid:7588708
Mugiya S et al. Renal blood flow, fibrinolysis, and platelet aggregation following tacrolimus (FK 506) treatment in rats. 1995 Thromb. Res. pmid:8533130
Stemmer PM et al. Factors responsible for the Ca(2+)-dependent inactivation of calcineurin in brain. 1995 FEBS Lett. pmid:7589543
Kaplan A et al. The effects of cyclosporin A and FK506 on proliferation and IL-8 production of cultured human keratinocytes. 1995 J. Dermatol. Sci. pmid:8534611
Zhu X et al. Enhancing and suppressive effects of immunosuppressants cyclosporin A, FK506, and KM2210 on the colony formation of murine bone marrow cells. 1995 Ann. Hematol. pmid:8534762
Ockenfels HM et al. Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. 1995 Dermatology (Basel) pmid:8534940
Vilquin JT et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. 1995 Hum. Gene Ther. pmid:8573612
Díaz M et al. [Tacrolimus (FK 506): an immunosuppression alternative in solid organ transplantation. (Part 2)]. 1995 Apr-Jun Rev Med Univ Navarra pmid:7569553
Hisatomi K et al. Effect of dose of cyclosporine or FK506 and antithrombotic agents on cardiac allograft vascular disease in heterotopically transplanted hearts in rats. 1995 Jan-Feb J. Heart Lung Transplant. pmid:7537098
Díaz M et al. [Tacrolimus (FK 506): immunosuppressive alternative to solid organ transplant (Part 1)]. 1995 Jan-Mar Rev Med Univ Navarra pmid:14735715
Kawahara K et al. Effects of deoxyspergualin on bronchial anastomosis healing in canine pulmonary allografts. 1995 Jul-Aug J. Heart Lung Transplant. pmid:7578196
Motoyama K et al. Pretransplant intrathymic inoculation of donor antigen combined with FK506 treatment: prolongation of survival of cardiac, but not renal, allografts in rats. 1995 Mar-Apr World J Surg pmid:7538717
Okudaira H et al. Enhanced production and gene expression of interleukin-5 in patients with bronchial asthma: possible management of atopic diseases by down-regulation of interleukin-5 gene transcription. 1995 May-Jun Int. Arch. Allergy Immunol. pmid:7542077
Su Q et al. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. 1995 May-Jun Ren. Physiol. Biochem. pmid:7542793
Hayashi S et al. Evidence that donor pretreatment with FK506 has a synergistic effect on graft prolongation in hamster-to-rat heart xenotransplantation. 1995 May-Jun J. Heart Lung Transplant. pmid:7544621
Castillo Lugo JA Clinical and experimental immunosuppression. 1995 May-Jun Bol Asoc Med P R pmid:8573248
Seifeldin R Drug interactions in transplantation. 1995 Nov-Dec Clin Ther pmid:8750397
Schreiber SL and Crabtree GR Immunophilins, ligands, and the control of signal transduction. 1995-1996 Harvey Lect. pmid:9127988
Jin MB et al. Protective effect of FK 506 on hepatic energy metabolism in warm ischemic canine livers induced by total hepatic vascular exclusion. 1996 Transplant. Proc. pmid:8623243
Smit JA et al. Induction of primate TH2 lymphokines to suppress TH1 cells. 1996 Transplant. Proc. pmid:8623334
Appignani BA et al. Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. 1996 AJR Am J Roentgenol pmid:8623651
Asfar S et al. Small bowel transplantation. A life-saving option for selected patients with intestinal failure. 1996 Dig. Dis. Sci. pmid:8625758
Esquivel CO et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. 1996 Transplantation pmid:8607198
Peters KP et al. The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. 1996 J. Mol. Biol. pmid:8609611
Lu YF et al. FK506, a Ca2+/calmodulin-dependent phosphatase inhibitor, inhibits the induction of long-term potentiation in the rat hippocampus. 1996 Neurosci. Lett. pmid:8907327
Ye Q et al. Persistence of donor cells and incidence of graft-versus-host disease after simultaneous small bowel and bone marrow transplantation. 1996 Transplant. Proc. pmid:8907895
Becker G et al. Diltiazem minimizes tubular damage due to FK506-mediated nephrotoxicity following ischemia and reperfusion in rats. 1996 Transpl. Immunol. pmid:8762016
Paus R et al. Hair growth control by immunosuppression. 1996 Arch. Dermatol. Res. pmid:8818191
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplant. Proc. pmid:8962225
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Kliem V et al. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. 1996 Transplant. Proc. pmid:8962227
Michel G et al. Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). 1996 Biochem. Pharmacol. pmid:8787547
Gonschior AK et al. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. 1996 Clin. Chem. pmid:8787699
Karashima T et al. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. 1996 J. Dermatol. Sci. pmid:8884530
Monfar M and Blenis J Inhibition of p70/p85 S6 kinase activities in T cells by dexamethasone. 1996 Mol. Endocrinol. pmid:8885245
Kawabe A et al. Anti-adhesion (anti-ICAM-1 and anti-LFA-1) therapy in a rat pancreas transplantation model. 1996 Transplant. Proc. pmid:8658893
Hayakawa K et al. Maintenance of unresponsiveness by short-term pulse therapy with FK 506 in rat transplantation. 1996 Transplant. Proc. pmid:8658904
Cox KL and Freese DK Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation. 1996 Clin Invest Med pmid:8889279
Mach-Pascual S et al. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. 1996 Am. J. Hematol. pmid:8701950
Hemenway CS and Heitman J Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 1996 J. Biol. Chem. pmid:8702500
Eckert B et al. Calcium-mobilizing insulin secretagogues stimulate transcription that is directed by the cyclic adenosine 3',5'-monophosphate/calcium response element in a pancreatic islet beta-cell line. 1996 Endocrinology pmid:8536617
Wesselborg S et al. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). 1996 J. Biol. Chem. pmid:8576111